IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

Core Insights - IN8bio, Inc. reported significant financial progress and advancements in its clinical γδ T cell therapy programs and T cell engager platform in 2025, with a focus on addressing unmet medical needs in cancer and autoimmune diseases [2] Financial Highlights - The company reduced its full-year net loss by 36% year-over-year, reporting a net loss of $19.4 million for 2025 compared to $30.4 million in 2024 [11][18] - Cash position improved significantly, with $27.1 million as of December 31, 2025, compared to $11.1 million at the end of 2024 [11][20] - Research and Development (R&D) expenses decreased to $10.2 million in 2025 from $17.0 million in 2024, while General and Administrative (G&A) expenses also saw a reduction to $9.7 million from $12.6 million [11][22] Clinical Developments - Updated clinical data from the INB-200 and INB-400 trials showed that patients treated with DeltEx DRI γδ T cells nearly doubled the median progression-free survival (mPFS) to 13.0 months compared to 6.6 months in the standard-of-care control group, representing a 97% improvement [5][7] - The median overall survival (mOS) for repeat dose patients had not yet been reached at 17.2+ months, surpassing the 13.2-month final mOS for the standard-of-care control arm [7] - No dose-limiting toxicities or severe adverse events were reported, reinforcing the potential of repeat-dose γδ T cell therapy to improve outcomes in newly diagnosed glioblastoma [12] Financing and Strategic Initiatives - IN8bio announced a private placement of up to $40.2 million, with an initial closing of $20.1 million, expected to extend the cash runway into the first half of 2027 [3][6] - Proceeds from the financing will support IND-enabling studies for the INB-619 γδ T cell engager and further discussions with the FDA regarding clinical pathways for the GBM program [6] Leadership Update - Kate Rochlin, Ph.D., was promoted to President and Chief Operating Officer, continuing to oversee the company's operations and strategic execution as it advances its clinical pipeline [9] Anticipated Milestones - Guidance from the FDA on potential regulatory pathways is expected in the second half of 2026, along with additional clinical updates on GBM programs and preclinical data for INB-619 [13]